

Vadim S Koshkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8271706/publications.pdf>

Version: 2024-02-01

67
papers

2,453
citations

567281

15
h-index

233421

45
g-index

69
all docs

69
docs citations

69
times ranked

6333
citing authors

#	ARTICLE	IF	CITATIONS
1	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	3.9	15
2	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
3	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	4
4	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718.	5.4	32
5	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	5.0	12
6	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
7	Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 189-194.	1.9	2
8	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205.	4.1	26
9	Making National Cancer Institute's Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. <i>JMIR Cancer</i> , 2022, 8, e33859.	2.4	0
10	PIVOT-10: Phase II study of bempagaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021, 17, 137-149.	2.4	5
11	Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. <i>JCO Oncology Practice</i> , 2021, 17, e377-e385.	2.9	14
12	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 15.	3.0	13
13	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.	1.6	0
14	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 414-419.	0.4	3
15	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
16	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 443-443.	1.6	4
17	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 445-445.	1.6	2
18	Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 442-442.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	4.1	15
20	<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. , 2021, 9, e002127.		24
21	Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. <i>Clinical Cancer Research</i> , 2021, 27, 5123-5130.	7.0	65
22	Reply to R. Kebudi et al. <i>JCO Oncology Practice</i> , 2021, 17, 364-364.	2.9	0
23	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.1	149
24	Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review. <i>Translational Andrology and Urology</i> , 2021, 10, 4022-4035.	1.4	3
25	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.	2.9	1
26	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
27	Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5022-5022.	1.6	42
28	First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17109-e17109.	1.6	2
29	Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 502-502.	1.6	3
30	Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 297-297.	1.6	0
31	Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 187-187.	1.6	1
32	PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS589-TPS589.	1.6	0
33	Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17025-e17025.	1.6	1
34	Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 559-566.	2.6	12
35	Systematic Review: Targeting HER2 in Bladder Cancer. <i>Bladder Cancer</i> , 2019, 5, 1-12.	0.4	34
36	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	7.0	48

#	ARTICLE	IF	CITATIONS
37	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	3.1	11
38	The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. <i>Translational Cancer Research</i> , 2019, 8, S130-S132.	1.0	1
39	Circulating cellular biomarkers associated with delayed time to progression among bladder cancer patients treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 398-398.	1.6	0
40	Treatment sequencing of anti-PD-1/PD-L1 and carboplatin (carbo)-based chemotherapy (chemo) in cisplatin-ineligible patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4541-4541.	1.6	0
41	PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4594-TPS4594.	1.6	3
42	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	3.6	14
43	Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 48.	4.0	40
44	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e879-e892.	1.9	25
45	Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. <i>Translational Andrology and Urology</i> , 2018, 7, 504-507.	1.4	3
46	Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. <i>Therapeutic Advances in Urology</i> , 2018, 10, 445-454.	2.0	10
47	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1019-1040.	2.0	55
48	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
49	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 3333-3340.	8.2	43
50	Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4546-4546.	1.6	2
51	First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16517-e16517.	1.6	3
52	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 439-439.	1.6	4
53	Prognostic value of CD56, ASCL1, and other biomarkers in small cell bladder cancer (SCBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 452-452.	1.6	0
54	Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 432-432.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. Journal of Clinical Oncology, 2018, 36, 305-305.	1.6	1
56	Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.. Journal of Clinical Oncology, 2018, 36, 446-446.	1.6	0
57	The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 599-599.	1.6	0
58	Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.. Journal of Clinical Oncology, 2017, 35, 4586-4586.	1.6	10
59	Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, e16031-e16031.	1.6	1
60	Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC).. Journal of Clinical Oncology, 2017, 35, 382-382.	1.6	2
61	Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice.. Journal of Clinical Oncology, 2017, 35, 390-390.	1.6	0
62	Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype.. Journal of Clinical Oncology, 2017, 35, 4529-4529.	1.6	1
63	Emerging therapeutics in refractory renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2016, 17, 1225-1232.	1.8	15
64	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. Journal of Clinical Oncology, 2016, 34, 3680-3685.	1.6	17
65	Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC).. Journal of Clinical Oncology, 2016, 34, e16037-e16037.	1.6	0
66	CAD-associated Reader Error in CT Colonography. Academic Radiology, 2012, 19, 801-810.	2.5	4
67	Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain. Brain Research, 2005, 1065, 8-19.	2.2	77